MedAssets manages approximately $59bn in annual supply spend on behalf of its clients.
"With MedAssets serving four out of five US hospitals and approximately 123,000 non-acute healthcare providers, we are very excited to enter into this exclusive agreement for our BoneScalpel and SonicOne surgical technologies.
"This is simply a great opportunity for many more healthcare facilities and their patients to ultimately benefit from our technology," commented Michael A McManus, President and CEO of Misonix."
Misonix designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies.
Addressing a combined market estimated to be in excess of $3bn annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.
